Skip to content
Search

Latest Stories

TECHNOLOGY: Adios, final checks!

Tariq Muhammad explains how new technology is spelling the end of the traditional ‘final check’ in a pharmacy…

Any mistake made in the pharmacy can be a serious concern. Something as simple as attaching the label on the wrong drug can have profound consequences. Over the years there have been many well publicised cases where a dispensing error has gone on to cause serious harm, and in some cases death, to a patient. A quick Google search will return countless news articles of lives being destroyed by a single incident that can be traced back to a human error at the pharmacy.


The rate of actual dispensing errors varies between 0.2 per cent and 3 per cent nationally, depending on which report you read. Whether or not we agree on the actual number, we can all agree on their signifycance. Dispensing errors don’t just cause harm to the patient. They can damage the reputation of the pharmacy business and potentially end the pharmacist’s career.

Until recently, a dispensing error causing the death of a patient was deemed a criminal offence and there have been high profile cases where pharmacists have been handed jail terms for fatal incidents. In 2018, after several years of campaigning, the law was finally changed to decriminalise dispensing errors but this does not mean that pharmacists can get away scot-free. Errors reported to GPhC may result in Fitness to Practice cases and at the very least the psychological trauma of an incident will weigh as heavily on a pharmacist as it does on a patient and their family.

Final check

For years, the pharmacy professions defence against dispensing errors has been the Final Check. It is the critical step in the dispensing process before the patient’s medication is bagged and handed out. It is the last opportunity for pharmacy staff to catch an error relating to quantity, strength, expiry date, or dose before it leaves the premises and potentially goes off to harm a patient.

The Final Check is the reason we see pharmacists waving boxes around in the air followed by a scribble in a box where it says “checked by”. In our fight against dispensing errors we see pharmacies plastered in posters highlighting the most popular “Look Alike Sound Alike” drugs that staff need to watch out for. We see pharmacies buried with SOPs meticulously setting out step by step how to check a labelled item.

But if this is our defence, then I would argue it’s pretty weak. These measures were never going to eradicate dispensing errors. They tick a box to show our regulators that we are exercising our professional responsibility. At best these processes might even capture a few errors up to the point of labelling, but still don’t stop mistakes that happen after this step such as packaging errors or handing out the whole supply to the wrong patient.

Delegating final checks to ACTs has helped remove some of the pressure from the pharmacist in busy pharmacies. However, this has not reduced the risk of errors given that any human is just as likely to make a human error no matter how vigilant they try to be.

So is this it? Is this the best we can do as a profession to ensure patient safety?

Graph 1 Fig: Users feedback on their Dispensing Errors since using barcode validation

Advent of technology

Titan PMR created a digital workflow that allowed the pharmacist to carry out the clinical check up front and all remaining steps to be carried out using barcode validation.

After the pharmacist has cleared the prescription for dispensing, a picking sheet tells the staff what stock to get. During the labelling process, the manufacturer’s barcode is scanned. If the scanned product is the correct drug, correct strength, correct quantity and correct date, then a dispensing label is produced. If not, then no label is produced but a near miss is recorded.

Likewise, when it comes to packaging the dispensing labels are scanned one at a time before a bag label is produced ensuring that there is no mix up between patient’s drugs.

When it comes to handing out, the package label is scanned to ensure that the right patient is verified before the package is transferred to the patient.

This digital workflow has enabled pharmacies to operate the dispensing process without the need for any Final Checks except for split packs, controlled drugs and other high risk drugs.

In a survey of 30 Titan pharmacies, who had been using the system for over a year, they compared their experiences of the barcode validation approach with their previous traditional final check process and the results have been quite remarkable.

The graph shows that 100 per cent of users reported a Reduction or Very Significant Reduction in Actual Labelling and Packaging Errors (i.e. those that leave the pharmacy). 93 per cent also saw a reduction in Handout errors. On average the pharmacies reported a 90 per cent reduction in actual errors between Pre- and Post-Titan implementation.

Future of final checks

Let’s face it, the Final Check, whether carried out by a pharmacist or ACT, is a consequence of the manual processes we have inherited from the days of FP10 paper prescriptions and traditional PMR dispensing processes. Contrary to popular belief, the Final Check is not a defined term in the Medicines Act 1968, but rather the only way we could think of to ensure the final supply matched up with the initial prescription.

In the last 10 years pharmacy dispensing volumes have increased by 25 per cent alongside the addition of new roles and services now being offered by pharmacists. This has added considerable pressure and distractions on already stretched teams who are expected to continue supplying medicines without making a single mistake.

The concept of old school scribbling on labels and relying on the vigilance of pharmacists or ACTs at the end of every transaction is no longer a sustainable model to ensure patient safety. The advent of EPS and new technology has given us an opportunity to reconsider the whole process and introduce an end-to-end digital workflow utilizing barcoding to validation each step of the way, helping us address packaging errors and handout errors as well as dispensing errors.

I believe the Final Check has had its final day and as a profession we should consider making barcode validation a mandatory process in every pharmacy. Surely, the evidence speaks for itself.

Tariq Muhammad is CEO of Invatech Health.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less